P466 Tofacitinib for the treatment of ulcerative colitis: Up to 5.4 years of safety data from global clinical trials
Bibliographic record
Abstract
Tofacitinib is an oral, small-molecule Janus kinase inhibitor approved in several countries for the treatment of ulcerative colitis (UC). The efficacy and safety of tofacitinib as UC induction and maintenance therapy were evaluated in Phase (P) 21 and P32 randomised, placebo-controlled studies, and in an ongoing, open-label, long-term extension (OLE) study.3 We report updated tofacitinib safety analyses from the UC programme, with exposure up to 5.4 years. Patients who received placebo, tofacitinib 5 or 10 mg twice daily (BID) were analysed as two cohorts: Maintenance (P3 maintenance, n = 592) and Overall (patients receiving tofacitinib 5 or 10 mg BID in P2, P3 or the OLE study, n = 1157; 2050.5 patient-years’ exposure; data at November 2017). Proportions and incidence rates (IR; unique patients with events per 100 patient-years) were evaluated for adverse events (AEs) of special interest. Opportunistic infections, malignancies, major adverse cardiovascular events (MACE) and gastrointestinal perforations were reviewed by independent adjudication committees. Results in the overall Ccohort based on the previous December 2016 data cut are presented for context. In total, 1157 patients received ≥1 dose of tofacitinib 5 or 10 mg BID. Demographics and disease characteristics were generally similar among treatment groups across cohorts. For the Overall Cohort, most patients (n = 956, 83%) received an average tofacitinib dose of 10 mg BID. IR for AEs of special interest were: death, 0.2; serious infection, 1.9; herpes zoster, 3.8; opportunistic infection, 1.2; malignancy (excluding non-melanoma skin cancer [NMSC]), 0.6; NMSC, 0.8; MACE, 0.3; and gastrointestinal perforation, 0.1. The safety profile of tofacitinib in patients with UC was manageable, and similar to the tofacitinib rheumatoid arthritis programme and that of other UC therapies including biologics. IR for AEs of special interest did not increase with longer exposure relative to previously reported analyses from the OCTAVE programme. A dose-dependent risk of herpes zoster was observed. Table. Baseline demographics and disease characteristics, and IR (unique patients with event per 100 pt-years) for AEs of special interest in the tofacitinib UC programme, for each cohort Reference 1. Sandborn WJ, Ghosh S, Panes J et al. Tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367:616-24. doi:10.1056/NEJMoa1112168 2. Sandborn WJ, Su C, Sands BE. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017;376:1723–36. doi:10.1056/NEJMoa1606910 3. Lichtenstein GR, Loftus Jr EV, Bloom S. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of ulcerative colitis: open-label, long-term extension study. Am J Gastroenterol. 2017;112(S1). Abstract 714,
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.038 | 0.031 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.003 | 0.004 |
| Bibliometrics | 0.001 | 0.003 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.003 | 0.003 |
| Open science | 0.001 | 0.002 |
| Research integrity | 0.002 | 0.004 |
| Insufficient payload (model declined to judge) | 0.005 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".